DOTA-NOC, DOTA-[Nal3]-octreotide
|
|
DOTA-NOC, DOTA-[Nal3]-octreotide Eigenschaften
- Sequenz
- DOTA-{d-Phe}-Cys-{Nal}-{d-Trp}-Lys-Thr-Cys-Thr-ol (Disulfide bridge: Cys2-Cys7)
- InChIKey
- VMOLIPGHXGTESU-UHFFFAOYSA-N
- CAS Datenbank
- 619300-53-7
Sicherheit
DOTA-NOC, DOTA-[Nal3]-octreotide Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Colourless to off-white lyophilised solidDOTA-NOC, DOTA-[Nal3]-octreotide Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
DOTA-NOC, DOTA-[Nal3]-octreotide Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 35)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate | |
---|---|---|---|---|---|
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21622 | 55 |
Shenzhen Nexconn Pharmatechs Ltd | +86-755-89396905 +86-15013857715 |
admin@nexconn.com | China | 10406 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19552 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 |
marketing@targetmol.com | United States | 32376 | 58 |
Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 |
sales@sarms4muscle.com | China | 10473 | 58 |
Alfa Chemistry | +1-5166625404; |
Info@alfa-chemistry.com | United States | 20405 | 58 |
Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 |
sales@molcore.com | China | 49734 | 58 |
Changsha MOL Changes Biotechnology Co., Ltd. | +8619375158599 |
info@molchanges.com | China | 5220 | 58 |
Hangzhou Baige Pharmaceutical Technology Co. , Ltd. | 0571-85350119 15888826472 |
15888826472@163.com | China | 2729 | 58 |
Creative Peptides | |
info@creative-peptides.com | United States | 6083 | 56 |
- DOTA-NOC
- DOTA-NOC acetate
- L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-3-(1-naphthalenyl)-L-alanyl-Dtryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2)-disulfide
- DOTA-NOC, DOTA-[Nal3]-octreotide
- L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-3-(1-naphthalenyl)-L-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide
- DOTA-NOC619300-53-7
- DOTA-[Nal3]-octreotide
- 2-[[10-(4-aminobutyl)-7-(1-hydroxyethyl)-13-(1~{H}-indol-3-ylmethyl)-16-(naphthalen-1-ylmethyl)-6,9,12,15,18-pentaoxo-19-[[3-phenyl-2-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propanoyl]amino]-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]-3-hydroxybutanoic acid
- FC-2154
- L-Cysteinamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-3-(1-naphthalenyl)-L-alanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
- 619300-53-7
- C69H94N14O17S2
- C69H92N14O18S2